News

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population."

Powers, whose father, sister, and brother are ophthalmologists, has held senior executive positions in strategic planning, marketing, and commercial and medical affairs at vision-focused companies.

Look beyond isolated treatment of the eye to address systemic factors.

Adam Muzychuk, MD, BSc, FRCSC discusses his presentation, "Outcomes of an ultra-low cylinder powered (0.90) toric versus non-toric in low astigmatic patients undergoing cataract surgery."

A brief analysis showed that ChatGPT 3.5 performed better.

According to the company, the feedback from the interactive meetings will provide guidance for the path to a PMA submission.

At the 2024 ASCRS Greg Kunst, CEO of Aurion Biotech relayed the latest news from Aurion and the company's work in cell therapies for corneal endothelial disease.

Closed globe ocular injury often leads to macular pathology

At this year's ASCRS meeting in Boston, Massachusetts, Ophthalmology Times Europe caught up with Eris Jordan, OD talked about the big plans the Boston-based startup has for the year ahead. Watch the full video to find out what's in store for the company and its novel cell therapy in Japan, Canada and the United States in 2024.

David Eichenbaum, MD, discusses his experiences with aflibercept, faricimab.

At this year's ASCRS meeting, J. Morgan Micheletti, MD talked about myriad research projects he discussed at the meeting and also emphasized the importance of the Young Eye Surgeons (YES).

At this year's ASCRS meeting in Boston, Massachusetts, Pete England gave an update on ViaLase's development on the first femtosecond laser for the treatment of open-angle glaucoma.

According to researchers, insights into the ocular microbiome could have implications beyond eye health.

Need to eliminate errors results in optimization of training of novice surgeons.

At this year's ASCRS meeting in Boston, Massachusetts, Leonard Borrmann, CEO at Centricity Vision, about the company's new product ZEPTOLink, including first-in-human data.

According to the company, the grant funding from the Choroideremia Research Foundation is in support of validating functional vision assessments for patients with profound blindness.

The molecule is being evaluated in 2 phase 3 clinical trials for wet AMD and is administered via intravitreal injection in combination with standard-of-care anti–VEGF-A therapy.

The LYNX-2 Phase 3 study is evaluating phentolamine ophthalmic solution 0.75% for the treatment of decreased visual acuity under low light conditions following keratorefractive surgery

Scientists at the National Institutes of Health use artificial intelligence called ‘P-GAN’ to improve next-generation imaging of cells in the back of the eye.

VG901 is designed to deliver a functional CNGA1 gene to retinal photoceptor target cells in patients diagnosed with retinitis pigmentosa.

The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease

Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment on macular degeneration-treated mice in space.

Authors explained that Nfe2l gene family members -1, -2, and -3 mediate the cellular response to oxidative stress, including in the CNS

Neda Nikpoor, MD, shares highlights from her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.

Elizabeth Yeu, MD, discusses a case report for how the triple procedure can be beneficial for different patient populations in her ASCRS presentation, 'Human corneal endothelial cell transplantation combined with cataract extraction and PCIOL in subject with corneal edema.'

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.